Intrexon (XON) Share Price May Be About to Change Direction; BofA Merrill Downgrades Them

July 16, 2018 - By Catherine Diaz

Intrexon Corporation (NYSE:XON) Logo

Investors sentiment increased to 1.78 in Q1 2018. Its up 0.40, from 1.38 in 2017Q4. It improved, as 20 investors sold Intrexon Corporation shares while 26 reduced holdings. 24 funds opened positions while 58 raised stakes. 106.32 million shares or 10.20% more from 96.48 million shares in 2017Q4 were reported.

Hightower Advsr Limited Liability Co owns 39,833 shares. Michael & Susan Dell Foundation stated it has 432,878 shares or 10.39% of all its holdings. 249 are held by Ironwood Finance Lc. Tocqueville Asset L P holds 0% or 16,600 shares. Amalgamated Comml Bank invested 0.01% in Intrexon Corporation (NYSE:XON). Comml Bank Of America Corp De invested in 562,159 shares. Ubs Asset Americas Inc invested 0% of its portfolio in Intrexon Corporation (NYSE:XON). Greenwich Wealth Mgmt Limited Liability invested in 0.12% or 50,000 shares. Stifel Corp holds 0.01% or 103,385 shares. Creative Planning stated it has 73,206 shares or 0% of all its holdings. 6,671 are held by Great West Life Assurance Can. Fmr Limited holds 0.01% or 5.28 million shares in its portfolio. Legal General Group Public Ltd Company accumulated 30,010 shares. Raymond James Assocs invested in 33,917 shares or 0% of the stock. Grp One Trading Limited Partnership accumulated 41,204 shares or 0.01% of the stock.

Since January 19, 2018, it had 2 insider purchases, and 0 selling transactions for $112.50 million activity.

Intrexon (XON) Receives a Downgrade

BofA Merrill has cut the rating for shares of Intrexon (XON) to a solid “Underperform” in a research report sent to clients and investors on Monday morning. XON’s previous rating by the firm was a “Neutral”.

The stock decreased 4.42% or $0.68 during the last trading session, reaching $14.7. About 941,279 shares traded. Intrexon Corporation (XON) has declined 29.17% since July 16, 2017 and is downtrending. It has underperformed by 41.74% the S&P500.

Analysts await Intrexon Corporation (NYSE:XON) to report earnings on August, 8. They expect $-0.23 earnings per share, down 43.75 % or $0.07 from last year’s $-0.16 per share. After $-0.17 actual earnings per share reported by Intrexon Corporation for the previous quarter, Wall Street now forecasts 35.29 % negative EPS growth.

Intrexon Corporation operates in the synthetic biology field in the United States. The company has market cap of $1.92 billion. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It currently has negative earnings. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform.

More recent Intrexon Corporation (NYSE:XON) news were published by: Benzinga.com which released: “31 Stocks Moving In Monday’s Mid-Day Session” on July 16, 2018. Also Streetinsider.com published the news titled: “Pre-Open Movers 07/16: (CODA) (TXNP) (ARNC) Higher; (XON) (FNKO) (HAS) Lower (more…)” on July 16, 2018. Streetinsider.com‘s news article titled: “BofA/Merrill Lynch Downgrades Intrexon (XON) to Underperform Citing Limited NT Catalysts to Drive Upside” with publication date: July 16, 2018 was also an interesting one.

Intrexon Corporation (NYSE:XON) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.